ArticleESMO real world data and digital oncology2026
Real-world outcomes of chemoimmunotherapy in advanced biliary tract cancer: a multicenter study with a propensity-matched historical cohort.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biliary tract cancer (BTC) comprises a heterogeneous group of malignancies, often diagnosed at advanced stages. Phase III trials have shown that adding immune checkpoint inhibitors (ICIs) to gemcitabine and cisplatin improves survival, supporting their use as first-line therapy; however, real-world evidence remains limited. Materials and methods: We conducted a multicenter observational study including patients with advanced BTC treated with ICI-based regimens plus chemotherapy. Clinical data were retrospectively collected. Overall survival (OS) was estimated using the Kaplan-Meier method, and prognostic factors were evaluated with multivariate Cox regression. A historical control cohort without ICI exposure was analyzed using propensity score matching. Results: A total of 152 patients received ICI-based therapy (median age 66.5 years, 57.9% men, and 68.4% metastatic). The most common primary sites were intrahepatic cholangiocarcinoma (52.6%) and gallbladder carcinoma (23.7%). Durvalumab plus gemcitabine/cisplatin was used in 88.1% of cases. After a median follow-up of 8.3 months, the median OS was 15.5 months (95% confidence interval 12.3-21.5), and the response rate was 38.8%. Maintenance therapy was given to 37.5%, mainly as ICI monotherapy. Independent adverse prognostic factors included Eastern Cooperative Oncology Group performance status of >0 [hazard ratio (HR) 3.91], neutrophil-to-lymphocyte ratio of ≥3 (HR 1.98), and vascular invasion (HR 1.83). Ten (6.6%) grade ≥2 immune-related adverse events were reported. A propensity score-matched analysis showed improved survival with ICI versus the historical cohort without ICI (HR 0.61, Conclusion: In this real-world cohort, ICI plus chemotherapy achieved outcomes comparable with pivotal trials, supporting its effectiveness in broader populations and highlighting the need for improved access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.